3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Pancreatic Neoplasms
2
Carcinoma, Hepatocellular
2
Stomach Neoplasms
1
Rhabdomyosarcoma
1
Recurrence
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Diseases
1
Neuroblastoma
1
Neoplasm Metastasis
1
Medulloblastoma
1
Liver Neoplasms
1
Hepatoblastoma
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Fibrosis
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma
1
Breast Neoplasms
1
Basal Cell Nevus Syndrome
1
Astrocytoma
1
Interventions
pembrolizumab
29
Carboplatin
10
Surveys and Questionnaires
9
Paclitaxel
9
Trastuzumab
8
Nivolumab
8
Cisplatin
8
Taxes
7
Gemcitabine
7
Bevacizumab
6
Specimen Handling
5
Oxaliplatin
5
Irinotecan
5
Fluorouracil
5
Cetuximab
5
Biopsy
5
spartalizumab
4
Leucovorin
4
Ipilimumab
4
Docetaxel
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
durvalumab
3
atezolizumab
3
aldesleukin
3
X-Rays
3
Psychiatric Rehabilitation
3
Magnetic Resonance Spectroscopy
3
Interviews as Topic
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
sonidegib
×
Gastrointestinal
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts